
BioVie Market Cap | BIVI
As of November 22, 2026 BioVie has a market cap of $ 5.72 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap BioVie
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.8 M | 2.44 M | 542 K | 11.6 M | 59.2 M | 37.2 M | 66.5 M | 31.7 M | 19.2 M | 17.5 M | 10.5 M | 15.7 M | 17.4 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 66.5 M | 542 K | 23.1 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Champions Oncology
CSBR
|
83.8 M | $ 4.34 | -1.36 % | $ 60 M | ||
|
Mesoblast Limited
MESO
|
12.5 B | $ 10.9 | -2.5 % | $ 13.2 B | ||
|
Mirum Pharmaceuticals
MIRM
|
5.45 B | $ 96.15 | 0.67 % | $ 4.83 B | ||
|
MannKind Corporation
MNKD
|
990 M | $ 3.85 | -2.66 % | $ 1.18 B | ||
|
Dyadic International
DYAI
|
31.5 M | $ 0.29 | -6.53 % | $ 10.5 M | ||
|
Merck & Co.
MRK
|
311 B | $ 133.34 | 0.4 % | $ 334 B | ||
|
Moderna
MRNA
|
19.4 B | $ 195.25 | -2.05 % | $ 76 B | ||
|
NuCana plc
NCNA
|
85.4 B | $ 0.75 | 4.39 % | $ 8.42 B | ||
|
Novartis AG
NVS
|
316 B | $ 150.51 | -0.47 % | $ 292 B | ||
|
Puma Biotechnology
PBYI
|
378 M | $ 7.05 | -1.05 % | $ 353 M | ||
|
Fulcrum Therapeutics
FULC
|
490 M | $ 3.69 | -0.67 % | $ 281 M | ||
|
PDS Biotechnology Corporation
PDSB
|
25 M | $ 0.79 | -2.58 % | $ 36.6 M | ||
|
Geron Corporation
GERN
|
1.06 B | $ 0.87 | -4.76 % | $ 580 M | ||
|
Pharming Group N.V.
PHAR
|
11.8 B | $ 11.54 | -5.18 % | $ 7.95 B | ||
|
Phathom Pharmaceuticals
PHAT
|
986 M | $ 4.65 | -8.46 % | $ 339 M | ||
|
Genmab A/S
GMAB
|
1.41 B | $ 50.36 | -1.93 % | $ 3.26 B | ||
|
Gossamer Bio
GOSS
|
107 M | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Grifols, S.A.
GRFS
|
4.52 B | $ 8.14 | -0.73 % | $ 5.53 B | ||
|
Liquidia Corporation
LQDA
|
2.95 B | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
GlaxoSmithKline plc
GSK
|
216 B | $ 47.8 | -0.05 % | $ 194 B | ||
|
MediciNova
MNOV
|
69.2 M | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
5.56 B | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
5.08 B | $ 1.24 | -12.34 % | $ 4.53 B | ||
|
InflaRx N.V.
IFRX
|
63.3 M | $ 1.05 | -3.67 % | $ 70.7 M | ||
|
Immunome
IMNM
|
1.89 B | $ 15.69 | -5.54 % | $ 1.37 B | ||
|
Immuron Limited
IMRN
|
231 M | $ 0.9 | 5.87 % | $ 208 M | ||
|
Incyte Corporation
INCY
|
19.5 B | $ 114.5 | -1.19 % | $ 22.4 B | ||
|
INmune Bio
INMB
|
28.2 M | $ 0.82 | -8.41 % | $ 20.3 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
12.3 B | $ 14.88 | 0.24 % | $ 12.4 B | ||
|
Regeneron Pharmaceuticals
REGN
|
81.3 B | $ 920.38 | -0.22 % | $ 96.3 B | ||
|
Ionis Pharmaceuticals
IONS
|
12.9 B | $ 26.58 | -2.37 % | $ 4.25 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
43.9 M | $ 1.06 | -10.92 % | $ 48.4 M | ||
|
Ironwood Pharmaceuticals
IRWD
|
100 M | $ 4.68 | -0.53 % | $ 757 M | ||
|
Kala Pharmaceuticals
KALA
|
1.63 M | $ 2.73 | -9.61 % | $ 22.2 M | ||
|
Intellia Therapeutics
NTLA
|
776 M | $ 10.02 | 5.24 % | $ 1.09 B | ||
|
Adagene
ADAG
|
224 M | $ 1.8 | -10.56 % | $ 106 M | ||
|
Denali Therapeutics
DNLI
|
2.41 B | $ 18.43 | 1.29 % | $ 3.18 B | ||
|
Pfizer
PFE
|
155 B | $ 27.4 | -0.62 % | $ 156 B | ||
|
Amarin Corporation plc
AMRN
|
5.8 B | $ 10.56 | -6.26 % | $ 4.38 B | ||
|
ImmuCell Corporation
ICCC
|
58 M | $ 11.08 | -0.81 % | $ 100 M | ||
|
Editas Medicine
EDIT
|
206 M | $ 1.63 | -4.68 % | $ 145 M | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
3.28 B | $ 93.83 | 0.32 % | $ 6.96 B | ||
|
Agios Pharmaceuticals
AGIO
|
1.63 B | $ 27.54 | -4.24 % | $ 1.6 B | ||
|
Royalty Pharma plc
RPRX
|
18.9 B | $ 68.45 | 1.08 % | $ 29.4 B | ||
|
Equillium
EQ
|
118 M | $ 1.06 | -5.36 % | $ 60.7 M | ||
|
Black Diamond Therapeutics
BDTX
|
125 M | $ 1.32 | -5.04 % | $ 75.1 M | ||
|
Abeona Therapeutics
ABEO
|
252 M | $ 2.42 | -1.17 % | $ 128 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
3.65 B | $ 17.1 | -2.79 % | $ 2.88 B | ||
|
Atossa Therapeutics
ATOS
|
46.7 M | $ 1.6 | -8.86 % | $ 13.8 M | ||
|
Cleveland BioLabs, Inc.
CBLI
|
56.9 M | - | -7.31 % | $ 49 M |